India carries the heaviest cervical cancer burden in the world. Around 96,000 women are newly diagnosed each year and roughly 60,000 die from it, according to the Indian Council of Medical Research's National Cancer Registry Programme. That is one Indian woman lost roughly every nine minutes to a cancer we know how to prevent.

Globally, India accounts for almost a quarter of all cervical cancer deaths, even though Indian women are about a sixth of the world's female population. The reason is not biology — it is access. Countries with organised screening programmes have cut their cervical cancer rates by 70 to 80 percent. India's national screening coverage still hovers in the low single digits.

What makes this preventable is the disease itself. Cervical cancer is almost never sudden. It begins with a common infection, drifts through a multi-year pre-cancer phase that has no symptoms, and only becomes invasive cancer 10 to 20 years later. Almost every Indian woman who ends up with invasive cervical cancer passed through a window — sometimes a decade long — during which a single screening test could have caught it.

Most deaths in India happen because women are diagnosed too late. Stage I cervical cancer has a 5-year survival of around 90 percent. Stage IV drops to roughly 15 percent. The screening test is what moves a woman from one column to the other.

Cervical cancer is caused almost entirely by persistent infection with high-risk human papillomavirus (HPV). HPV 16 and HPV 18 alone are responsible for around 70 percent of cases worldwide and in India. A further 20 percent come from five other high-risk strains — HPV 31, 33, 45, 52, and 58.

HPV itself is extremely common. Most sexually active adults will encounter it at some point, and in the great majority the immune system clears it silently within a year or two. The problem is the small fraction in whom a high-risk strain lingers. Over 5 to 20 years, persistent infection nudges normal cervical cells through pre-cancer stages (called CIN 1, CIN 2, and CIN 3) and eventually into invasive cancer.

This long, slow timeline is the gift cervical cancer gives us. A persistent HPV infection picked up by an HPV DNA test, or a pre-cancer change spotted on a Pap smear or VIA exam, can be treated long before it ever becomes cancer. The screening test does not just find cancer earlier; it usually finds it before it is cancer at all.

Risk factors that raise the chance of persistent HPV and progression include smoking, weakened immune systems (including HIV), long-term oral contraceptive use beyond 5 years, multiple childbirths, and other genital infections. None of these change the central fact that the cause is HPV, and almost the entire prevention story runs through vaccination and screening.

• VIA (Visual Inspection with Acetic Acid): A trained provider applies dilute vinegar to the cervix during a speculum exam. Pre-cancer areas turn briefly white and are visible to the naked eye. Single-visit, low-cost, and the backbone of government PHC and CHC programmes. Sensitivity around 70 percent.
• Pap smear (cervical cytology): A small brush collects cells from the cervix, sent to a lab. The standard screening test globally since the 1940s. Sensitivity 50 to 70 percent on a single test, which is why it is repeated every 3 years. Free at government centres; 500 to 2,000 rupees at private labs.
• HPV DNA test: A swab from the cervix is tested for the presence of high-risk HPV strains. Sensitivity above 90 percent. FOGSI 2023 now recommends HPV DNA as the preferred primary screen for women aged 30 and above where available. Private cost around 1,500 to 3,500 rupees.
• HPV plus Pap co-test: The most sensitive option, combining both. Recommended every 5 years if both come back negative. Most often used at private hospital chains and in higher-income screening pathways.
• Self-sampling HPV kits are now emerging in India through some clinics and digital health platforms. The woman collects her own vaginal swab in private and posts it to a lab. Studies show acceptability is high and accuracy is comparable to a clinician-collected sample — a powerful tool for reaching women who avoid speculum exams.

Visual Inspection with Acetic Acid is the screening test most likely to reach the largest number of Indian women in the next decade. It is cheap, requires no laboratory infrastructure, gives results in the same visit, and can be performed by trained nurses and ANMs, not just doctors.

The exam itself takes about 5 to 10 minutes. A speculum is inserted, the cervix is wiped with 3 to 5 percent acetic acid (essentially dilute white vinegar), and the provider watches for the area to turn white. The whitening — called acetowhite change — happens within about a minute over any patch of cells that may be pre-cancerous.

If the cervix looks normal, the result is negative and the woman is asked to come back in 3 to 5 years. If a white patch is seen, the woman is referred for confirmation by colposcopy or biopsy, or in some single-visit see-and-treat programmes, treated immediately with cryotherapy or thermal ablation on the same day.

VIA is not perfect. It catches about 70 percent of pre-cancer lesions and has a higher false-positive rate than Pap or HPV testing. But in the context of India — where most women have never had any screening at all — even an imperfect test that reaches a hundred million women is a transformational improvement over a perfect test that reaches only a few lakhs.

A Pap smear is what most urban Indian women will encounter at a private gynaecology clinic. The test itself takes about 5 minutes and is uncomfortable rather than painful. You lie on an exam couch, a speculum is gently inserted, and a soft brush sweeps cells from the outer cervix and inside the cervical canal. The cells go onto a slide or into a liquid medium and are sent to a cytology lab.

Results usually come back in 1 to 2 weeks. They are reported using the Bethesda system — words like NILM (normal), ASCUS (mild changes, uncertain meaning), LSIL (low-grade changes), HSIL (high-grade changes), and AGC (changes in glandular cells).

Try to schedule the test when you are not on your period. Avoid intercourse, vaginal medicines, douching, or tampon use for 24 to 48 hours before. None of these absolutely prevent the test, but they can sometimes blur the result.

If you have never had a Pap smear before and feel anxious, that is normal. For a fuller first-time guide including how to ask for it, what the room looks like, and how to advocate for yourself if a provider rushes, see pap-smear-first-time-india.

The HPV DNA test directly detects the presence of high-risk HPV strains in cervical cells, rather than waiting to see if those strains have already started changing the cells. Because it catches the cause, not just the consequence, its sensitivity is above 90 percent — far higher than Pap or VIA.

The collection is identical to a Pap smear: speculum, brush, cervical swab. In many private labs the same sample can be tested for both HPV and cytology — that combination is the co-test. The result is usually reported as HPV positive or negative, sometimes with the specific strain (16, 18, or other high-risk).

FOGSI's 2023 guidelines now position HPV DNA testing as the preferred primary screen for women aged 30 and above, with Pap as the next-best alternative and VIA where neither is available. WHO has been making the same shift globally.

A negative HPV test buys you a long interval — most guidelines recommend the next screen 5 years later. A positive HPV test does not mean cancer; it means the woman is at higher risk and needs a Pap smear, a repeat HPV test, or a colposcopy depending on her age and the specific strain.

For broader literacy on understanding the lab and scan reports your gynaecologist may order during this workup, see Understanding Scans, Labs & Reports: A Complete India Pregnancy Guide.

• Start at age 30. FOGSI 2023, the Indian Council of Medical Research, and WHO all align on age 30 as the starting point for the general population. Earlier screening is not recommended because pre-cancer changes before 30 usually resolve on their own.
• Screen earlier if higher risk. Women living with HIV, organ transplant recipients, women on long-term immunosuppressive medications, and those with a previous abnormal result should start earlier and screen more frequently — usually annually after diagnosis of HIV or every 2 years thereafter.
• Frequency depends on the test. HPV DNA every 5 years if negative; Pap every 3 years if negative; VIA every 3 to 5 years if negative; HPV plus Pap co-test every 5 years if both negative.
• Stop at age 65 if your last three screens were consistently normal and you have no history of CIN 2 or worse. Women with a history of significant pre-cancer should continue screening for at least 25 years after that diagnosis, regardless of age.
• Pregnancy is not a reason to skip a due Pap smear; it is safe to take during routine antenatal care. HPV testing is also safe in pregnancy.
• Vaccination does not replace screening. Even a fully vaccinated woman should still screen from age 30, because the vaccine does not cover every cancer-causing HPV strain.
• A hysterectomy that removed the cervix for a benign reason (such as fibroids) usually means cervical screening can be stopped. A hysterectomy that left the cervix in place, or that was performed for a cancer-related reason, means screening continues.

An abnormal screening result is not a cancer diagnosis. It is a flag that says further investigation is needed. The next step depends on exactly what was abnormal and on your age.

ASCUS (atypical squamous cells of undetermined significance) on a Pap, or a positive HPV test with a non-16/18 strain, usually means a repeat Pap or HPV test in 6 to 12 months, or a colposcopy depending on the lab's local protocol.

LSIL (low-grade squamous intraepithelial lesion) on a Pap means a colposcopy is usually recommended. Around 60 percent of LSIL changes regress on their own in younger women, so monitoring is often appropriate.

HSIL (high-grade squamous intraepithelial lesion) on a Pap, or HPV 16 or 18 positive, means a colposcopy with biopsy is strongly recommended without delay.

Colposcopy is a 15 to 20 minute outpatient exam. A magnifying device is used to inspect the cervix in detail and small biopsies may be taken from suspicious areas. The biopsy results determine the next step.

Biopsy results are graded as CIN 1, CIN 2, or CIN 3. CIN 1 is mild dysplasia and most often resolves on its own with monitoring every 6 to 12 months. CIN 2 and CIN 3 are moderate-to-severe pre-cancer and need treatment to prevent progression to invasive cancer.

• LEEP (Loop Electrosurgical Excision Procedure) is the most common treatment for CIN 2 and CIN 3 in India. A thin wire loop heated by an electric current shaves off the abnormal area of the cervix. The procedure is done in an outpatient setting under local anaesthesia and takes about 20 minutes. Cost is roughly 8,000 to 25,000 rupees at private centres; free at most government cancer hospitals.
• Cryotherapy freezes the abnormal cervical tissue with a probe cooled by nitrous oxide or carbon dioxide. It is simple, cheap, and well-suited to single-visit see-and-treat programmes where a VIA-positive woman is treated immediately on the same day. Cost is around 3,000 to 8,000 rupees privately; free in government programmes.
• Cone biopsy (conization) removes a cone-shaped piece of cervical tissue and is used when the lesion extends into the cervical canal, when LEEP cannot reach the affected area, or when microinvasion is suspected. It is done in an operating theatre under regional or general anaesthesia. Cost is around 15,000 to 40,000 rupees privately.
• Thermal ablation (thermocoagulation) is a newer alternative to cryotherapy that uses heat instead of cold. It is being increasingly adopted in India because it does not need gas cylinders and is more portable for rural programmes.
• After any pre-cancer treatment, follow-up screening is required at 6 to 12 months and then at regular intervals to make sure the lesion does not return. Most pre-cancer treatments are highly successful; recurrence rates after LEEP are well below 10 percent.

Invasive cervical cancer is staged from I to IV based on how far it has spread. Stage I is confined to the cervix; Stage II spreads to the upper vagina or surrounding tissue; Stage III reaches the lower vagina or pelvic wall; Stage IV has spread to the bladder, rectum, or distant organs.

Stage I and early Stage IIA are usually treated with radical hysterectomy plus pelvic lymph node dissection — the uterus, cervix, upper vagina, and nearby lymph nodes are removed. For very early Stage IA with no fertility plans, a simple hysterectomy may be enough. For young women wanting future fertility, a trachelectomy (removing the cervix but leaving the uterus) is possible in selected cases at specialised centres.

Stage IIB and above are usually treated with chemoradiation — external beam radiation plus internal brachytherapy, combined with cisplatin chemotherapy. Surgery is usually not the primary tool at these stages because the cancer has spread beyond the surgical reach.

Stage IV often involves a combination of chemotherapy, radiation, and palliative care depending on the spread. Newer immunotherapy options like pembrolizumab are being used in selected advanced cases at major Indian cancer centres.

Survival outcomes depend heavily on stage at diagnosis. Stage I cervical cancer has a 5-year survival of around 90 percent. Stage II is around 60 to 70 percent, Stage III around 30 to 50 percent, and Stage IV around 15 percent. Every step earlier in screening genuinely changes the outcome.

All treatment for cervical cancer in India should ideally happen at a comprehensive cancer centre — Tata Memorial Mumbai, Tata Memorial Centre Varanasi, Kidwai in Bengaluru, Cancer Institute (WIA) Chennai, AIIMS Delhi, RCC Thiruvananthapuram, and the various Apollo and HCG centres all have specialised gynaecologic oncology units.

• Ayushman Bharat PMJAY covers cervical cancer screening, diagnosis, and treatment for eligible families, including surgery, radiation, and chemotherapy. Cashless treatment is available at empanelled hospitals across India.
• Government cancer hospitals offer free or heavily subsidised cervical cancer treatment regardless of PMJAY status, including Tata Memorial Mumbai, Kidwai Bengaluru, Cancer Institute (WIA) Chennai, RCC Thiruvananthapuram, and AIIMS Delhi.
• Cervavac, the Indian HPV vaccine launched by Serum Institute of India in September 2022, is the cheapest entry point to the prevention side at around 2,000 rupees per dose. The 2024 Union Budget announced national rollout under the Universal Immunisation Programme for girls aged 9 to 14.
• Screening is free at most government primary health centres (PHCs) and community health centres (CHCs) through the National Cancer Screening Programme launched in 2016. Coverage is patchy by state but expanding.
• Many private hospital chains now bundle a screening package — Pap smear or HPV test plus a gynaecology consultation — for 1,500 to 4,000 rupees. Annual women's wellness check-ups often include it.
• The WHO 90-70-90 elimination strategy targets 90 percent HPV vaccination of girls by 15, 70 percent screening of women by ages 35 and 45, and 90 percent treatment of those needing it, by 2030. India's national programme is built around moving toward these numbers.

• Myth: no symptoms means no risk. Fact: early-stage cervical cancer and pre-cancer have no symptoms at all. By the time symptoms appear, the disease is usually already advanced. Screening is what catches it during the silent phase.
• Myth: a Pap smear is very painful. Fact: it is uncomfortable for a few seconds, not painful. A good clinician explains every step, uses a small or warmed speculum, and goes slowly. If a previous Pap was painful, ask for a smaller speculum and a slower pace next time.
• Myth: screening is only for sexually active or married women. Fact: any woman who has ever had any genital skin contact can carry HPV, and current Indian and global guidelines recommend screening for all women from 30 onward, irrespective of marital or sexual history.
• Myth: if I had the HPV vaccine, I do not need screening. Fact: even Gardasil 9 covers nine HPV strains, but around 10 to 30 percent of cervical cancers come from strains outside the vaccine. Screening from age 30 is still essential for life.
• Myth: cervical cancer runs in families and I do not have a family history. Fact: cervical cancer is overwhelmingly driven by HPV infection, not heredity. Almost any woman exposed to a high-risk HPV strain that persists can develop it, with or without a family history.
• Myth: a screening visit will tell my family I am sexually active. Fact: a screening visit is a routine adult health check, framed exactly the same way as a blood pressure check. You do not have to explain or justify it. Many private clinics now offer women-only OPDs and discrete billing.
• Cultural shame and silence remain the biggest non-medical barriers to screening uptake in India. Naming them openly within families is part of the work.

The hardest part of cervical cancer to communicate is that the screening years — the years where we can stop it — are completely silent. By the time the body throws up symptoms, the cancer is almost always past the easily curable stage.

When symptoms do appear, the most common are abnormal vaginal bleeding (between periods, after sex, or after menopause), foul-smelling vaginal discharge that does not respond to usual treatments, pelvic pain that is new or persistent, pain during intercourse, and unexplained leg swelling in more advanced disease.

Bleeding after sex is the symptom most often dismissed. Many women assume it is normal, hormonal, or related to dryness. It is almost always not normal at any age and should always be checked. See bleeding-after-sex-india for a fuller guide on this.

Postmenopausal bleeding is another red-flag symptom. Any vaginal bleeding more than a year after the last period is abnormal and needs prompt gynaecology review, both for cervical cancer and for endometrial cancer.

Other body-awareness practices, like a monthly breast self-exam, build the same instinct of noticing what has changed. See breast-self-exam-india.

Cervical cancer kills around 60,000 Indian women a year, and almost every one of those deaths was preventable with a 500-rupee test taken on time.

If you are 30 or older, book a screening this year. HPV DNA if you can access it, Pap if not, VIA if neither — any screening is dramatically better than none.

If your screening result comes back abnormal, do not panic and do not delay. Abnormal does not mean cancer. The next step is usually a colposcopy and biopsy, and pre-cancer found at this stage is highly treatable.

If there is a girl in your family aged 9 to 14, vaccinate her with Cervavac or Gardasil 9. Vaccination plus screening from 30 is what closes the cervical cancer chapter for the next generation.

If you have noticed bleeding after sex, bleeding between periods, postmenopausal bleeding, or persistent foul discharge, see a gynaecologist this week. Not next month. Cervical cancer in early stages is largely curable; the only barrier between an Indian woman and a normal life expectancy is the time it takes her to be seen.